Radius Health

950 Winter Street
Waltham
Massachusetts
02451
United States

Tel: 617-551-4000
Fax: 617-551-4701

About Radius Health

Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.

YEAR FOUNDED:
October 3, 2003
LEADERSHIP:
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
JOBS:
Please click here for Radius Health job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.

235 articles about Radius Health

Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update

11/3/2017

Third quarter reported sales of TYMLOS in the U.S. (the first full quarter since its launch) were approximately $3.5 million.
Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)

10/18/2017

Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018.
Radius Health To Announce Third Quarter 2017 Financial Results, Host Conference Call And Live Webcast On November 2, 2017

10/9/2017
Radius Health Initiates Phase I Clinical Trial Of RAD140 For The Treatment Of Hormone Receptor Positive Breast Cancer

9/29/2017
Radius Health Presents Positive Data For TYMLOS (Abaloparatide) Injection From The Activextend Trial At ASBMR 2017 Annual Meeting

9/11/2017
Radius Health Announces Pricing Of $300 Million Of 3.00% Convertible Senior Notes Due 2024

8/9/2017
Radius Health Announces Proposed Public Offering Of $300 Million Of Convertible Senior Notes Due 2024

8/8/2017
Radius Health Reports Second Quarter 2017 Financial And Operating Results And Provides Business Update

8/4/2017
Radius Health's Longtime CEO Out, Former Novo Nordisk A/S Exec Named New Leader

7/18/2017
Radius Health Announces New Employment Inducement Grant

7/18/2017
Radius Health Announces License And Development Agreement For Abaloparatide-SC With Teijin Limited In Japan

7/13/2017
Radius Health To Announce Second Quarter 2017 Financial Results, Host Conference Call And Live Webcast On August 3, 2017

7/7/2017
Radius Health Presents Positive Data From A Fully Enrolled Ongoing Phase I Study For Investigational Drug Elacestrant (RAD1901) At The 2017 ASCO

6/5/2017
Radius Health's Osteoporosis Drug Meets All Primary and Secondary Endpoints in Phase III Test

5/25/2017
Radius Health Announces New Employment Inducement Grant

5/16/2017
Radius Health Appoints Pharmaceutical Executive Jose Carmona As Chief Financial Officer

5/15/2017
Radius Health Reports First Quarter 2017 Financial And Operating Results

5/1/2017
FDA Approves Radius Health’s TYMLOS (Abaloparatide), A Bone Building Agent For The Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture

4/28/2017
Radius Health Announces Presentations At Upcoming Conferences And Its Plans To Announce First Quarter Financial Results On May 3, 2017

4/6/2017
Radius Health Release: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies

4/3/2017